Laura Butz, MD
Endocrinology, Diabetes & Metabolism · Columbus, OHNPI 1538452404
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Xeris Pharmaceuticals, Inc. accounts for 66.4% of it on its own, with 59 other manufacturers making up the rest. 2025 is the largest year on record at $30,874, 8.9 times the $3,465 reported in 2019.
Across 932 payments — averaging $47.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Xeris Pharmaceuticals, Inc.$29K
- Amgen$1K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Insulet Corporation$913
- Tandem Diabetes Care, Inc.$902
- plus $9K from 54 others
What the payments were for
- Speaking & faculty fees$24,85056%
- Travel & lodging$2,7326%
- Food & beverage$16,55937%
- Education$690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GVOKE HYPOPEN$27,007
- t-slim insulin pump$751
- FARXIGA$147
- TWIIST$139
- DEXCOM G6 TRANSMITTER$109
How this compares
$44,209 in reported general payments places this provider in the 85th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 105 | $182,118 |
| MounjaroTirzepatide | 86 | $113,680 |
| Teriparatide | 38 | $99,717 |
| ForteoTeriparatide | 18 | $75,323 |
| FarxigaDapagliflozin Propanediol | 49 | $62,304 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 40 | $61,445 |
| TrulicityDulaglutide | 31 | $49,605 |
| ProliaDenosumab | 26 | $45,626 |
| Humalog Kwikpen U-200Insulin Lispro | 20 | $39,687 |
| Tresiba Flextouch U-100Insulin Degludec | 49 | $32,892 |
| JardianceEmpagliflozin | 43 | $26,829 |
| Repatha SureclickEvolocumab | 25 | $25,458 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $25,257 |
| RybelsusSemaglutide | 17 | $24,293 |
| JanuviaSitagliptin Phosphate | 19 | $22,570 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Forteo, Trulicity | $1,172 | $238,607135 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,224 | $215,952143 claims |
| AstraZenecaFarxiga | $489 | $62,30449 claims |
| AmgenProlia | $1,268 | $45,62626 claims |
| Boehringer IngelheimJardiance, Tradjenta | $356 | $36,44556 claims |
| MerckJanuvia | $96 | $22,57019 claims |
| AbbVieSynthroid | $372 | $2,79841 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $394 | $1,927228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Columbus
- Elena ChristofidesColumbus$2.3M
- Samuel AndersonColumbus$556K
- Ravi DhawaleColumbus$175K
- Laura RyanColumbus$126K
- Kathleen WyneColumbus$88K
- Kathleen DunganColumbus$60K
- Jay PatelColumbus$60K
- Lawrence KirschnerColumbus$57K
- Shrikant TamhaneColumbus$55K
- Constantine KroustosColumbus$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.